Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Running, not enrolling · Phase 3

Conditions studied: Small Cell Lung Carcinoma Extensive Disease

In brief

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer

Key facts

Study ID

NCT03043872

Run by

AstraZeneca

People needed

987

Starts

2017-03-27

Expected to finish

2026-12-31

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically documented extensive disease. Brain metastases; must be asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.
• Suitable to receive a platinum-based chemotherapy regimen as 1st line treatment.
• Life expectancy ≥12 weeks at Day 1.
• ECOG 0 or 1 at enrolment.
• No prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines.

You may not qualify if…

• Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).
• Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS
• Active infection including tuberculosis, HIV, hepatitis B anc C
• Active or prior documented autoimmune or inflammatory disorders
• Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.

Where it is running

• Research Site — Scottsdale, Arizona, United States
• Research Site — Rogers, Arkansas, United States
• Research Site — Santa Monica, California, United States
• Research Site — New Haven, Connecticut, United States
• Research Site — Athens, Georgia, United States
• Research Site — Fort Wayne, Indiana, United States
• Research Site — Muncie, Indiana, United States
• Research Site — Leawood, Kansas, United States
• Research Site — Wichita, Kansas, United States
• Research Site — Paducah, Kentucky, United States
• Research Site — Grand Rapids, Michigan, United States
• Research Site — Mineola, New York, United States
• Research Site — Cleveland, Ohio, United States
• Research Site — Columbus, Ohio, United States
• Research Site — Harrisburg, Pennsylvania, United States
• Research Site — Sioux Falls, South Dakota, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Kennewick, Washington, United States
• Research Site — Buenos Aires, Argentina
• Research Site — Ciudad de Buenos Aires, Argentina
• Research Site — Mar del Plata, Argentina
• Research Site — Rosario, Argentina
• Research Site — San Miguel de Tucumán, Argentina
• Research Site — Linz, Austria
• Research Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.